Elina Koustoumpardi

Senior Consultant
Elina Koustoumpardi Antitrust Competition Charles River Associates

Elina Koustoumpardi joined CRA (formerly Lexecon) in 2002. During her tenure, she has advised clients in mergers, Art. 101 & 102 cases as well as follow-on damages cases arising from anti-competitive conduct both before the EU and national competition authorities in Europe, China and South Africa, in sectors ranging from pharmaceuticals, carton packaging, aviation, mining and telecoms.

In her more recent work she has provided economic advice to a large carton packaging producer being investigated for anti-competitive practices in China, has provided economic advice and supporting analysis in a number of pharmaceutical mergers including Novartis/GSK, Pfizer/Hospira, Teva/Mylan and co-authored a study on the economic impacts of changing exemption provisions during patent and SPC protection of pharmaceuticals in Europe.

Selected engagements

  • 01
    CAT approves class action settlement agreement in maritime cartel
    A CRA team, including Raphaël De Coninck, Elina Koustoumpardi, Oliver Wichert, Dominik Fischer, Francesca Garbin, Isabella Pandelli and Lorenzo Comito advised...
    View engagement
  • 02
    EC unconditionally approves $16.5bn acquisition of Catalent by Novo Holdings
    By providing additional fill-finish capacity, the transaction would enable Novo Nordisk to reach more obesity and diabetes patients faster. The Commission...
    View engagement
  • 03
    European Commission fines Teva €462.6 million for antitrust abuse
    The Commission found that Teva had abused its dominant position by engaging in two types of conduct. First, it misused the patent system to artificially...
    View engagement

Credentials

Get In Touch